Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.jhep.2004.07.028
DC FieldValue
dc.titleSafety and efficacy of alamifovir in patients with chronic hepatitis B virus infection
dc.contributor.authorSoon, D.K.W.
dc.contributor.authorLowe, S.L.
dc.contributor.authorTeng, C.H.
dc.contributor.authorYeo, K.P.
dc.contributor.authorMcGill, J.
dc.contributor.authorWise, S.D.
dc.date.accessioned2014-12-12T07:13:26Z
dc.date.available2014-12-12T07:13:26Z
dc.date.issued2004-11
dc.identifier.citationSoon, D.K.W., Lowe, S.L., Teng, C.H., Yeo, K.P., McGill, J., Wise, S.D. (2004-11). Safety and efficacy of alamifovir in patients with chronic hepatitis B virus infection. Journal of Hepatology 41 (5) : 852-858. ScholarBank@NUS Repository. https://doi.org/10.1016/j.jhep.2004.07.028
dc.identifier.issn01688278
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/115279
dc.description.abstractAlamifovir is a purine nucleotide analogue prodrug that shows potent activity against wild type and lamivudine resistant hepatitis B virus in preclinical studies. The aim of this study was to assess the safety and potential antiviral effects of alamifovir in humans. A randomised, placebo controlled, dose escalation study of oral alamifovir was conducted in 66 chronic hepatitis B infected patients who were selected based on stable HBV DNA (>10 5 copies/ml), with no significant liver pathology. They received either placebo or alamifovir at a total daily dose ranging from 2.5 to 20 mg in single or divided doses for 28 days and were followed up for approximately 12 weeks after cessation of treatment. All doses showed significant antiviral activity, with mean plasma viral load reductions ranging from 1.5 to 2.6 log 10 after 28 days of dosing. Once and twice daily regimen for the same daily dose (5 mg BID vs 10 mg QD, 10 mg BID vs 20 mg QD) showed no apparent difference in the rate and extent of viral decline, or viral reduction at day 28. Post-treatment viral suppression was dose dependent. There were no serious adverse events attributable to study drug, nor were significant dose related events identified. Alamifovir has shown potent in vivo anti-HBV activity, with a favourable safety profile. © 2004 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.jhep.2004.07.028
dc.sourceScopus
dc.subjectAlamifovir
dc.subjectHBV DNA
dc.subjectHBV patients
dc.typeArticle
dc.contributor.departmentINSTITUTE OF MOLECULAR & CELL BIOLOGY
dc.contributor.departmentSTATISTICS & APPLIED PROBABILITY
dc.description.doi10.1016/j.jhep.2004.07.028
dc.description.sourcetitleJournal of Hepatology
dc.description.volume41
dc.description.issue5
dc.description.page852-858
dc.description.codenJOHEE
dc.identifier.isiut000225309200021
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

14
checked on May 18, 2022

WEB OF SCIENCETM
Citations

9
checked on May 18, 2022

Page view(s)

187
checked on May 12, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.